TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) IN TREATMENT OF PATIENTS WITH SEVER AORTIC STENOSIS: METHOD REVIEW AND RESULTS FROM ZAGREB UNIVERSITY HOSPITAL CENTER
Joško Bulum, Zvonimir Ostojić, Maja Strozzi, Ivica Šafradin, Višnja Ivančan, Jadranka Šeparović-Hanževački, Vlatka Rešković-Lukšić, Bojan Biočina, Davor Miličić
Aortic stenosis is the most common valvular heart disease in western countries. Prevalence is increasing with age and is between 2–4% in population aged 65 or above. Despite cardiac surgery, almost third of patients did not undergo surgery due to too high surgical risk and comorbidities. Transcatheter aortic valve implantation (TAVI) is globally approved method for treating sever aortic stenosis in patients whose surgical risk is too high or they are declared as inoperable due to some other medical condition. Using this method, artificial biological valve is implanted, on beating heart, just using catheters at the place of degenerate native valve. In UHC Zagreb TAVI program has started in 2012, and since then, 44 procedures were performed. All procedures, together with periprocedural management were done following recent recommendations and guidelines of the European and American heart societies. This has resulted in very favorable treatment success. In this article, the most important TAVI facts have been highlighted followed by analysis of our TAVI results from the UHC Zagreb.